Skip to main content

Sirolimus News

FDA Approves Hyftor (sirolimus topical gel) for Facial Angiofibroma Associated with Tuberous Sclerosis

BETHESDA, Md., April 4, 2022 /PRNewswire/ – Nobelpharma America, LLC, a pharmaceutical and medical device company headquartered in Bethesda, Maryland, and a subsidiary of Nobelpharma Co., Ltd. in...

FDA Approves Rapamune (sirolimus) for Rare Lung Disease Lymphangioleiomyomatosis

May 28, 2015 – The U.S. Food and Drug Administration today approved Rapamune (sirolimus), to treat lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that primarily affects women of...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Sirolimus patient information at Drugs.com